Tailoring Treatment for Patients With HR+/HER2- Metastatic Breast Cancer: Examining the Role of Current and Emerging Endocrine Therapies
Podcast 2: Endocrine therapies for HR+/HER2- MBC: Knowing the limitations
Pre-Test

Questions marked with a * are required
100%
Contact Information
In the EMBER-3 trial, which of the following agents when given alone improved progression free survival in patients with ESR1 mutation, but not the study population as a whole?
In the EMBER-3 trial, which of the following agents when given alone improved progression free survival in patients with ESR1 mutation, but not the study population as a whole?
Acquired somatic mutations in which of the following genes limit the efficacy of first-generation endocrine therapies and has driven clinical trials for HR+/HER2- breast cancer in patients with this mutation?
Acquired somatic mutations in which of the following genes limit the efficacy of first-generation endocrine therapies and has driven clinical trials for HR+/HER2- breast cancer in patients with this mutation?
A 62-year-old woman with HR+/HER2- breast cancer experiences disease progression on first-line abemaciclib and aromatase inhibitor therapy after 18 months. She has no other comorbidities, and ctDNA analysis reveals an ESR1 mutation. Which of the following would be the ideal option at this time?
A 62-year-old woman with HR+/HER2- breast cancer experiences disease progression on first-line abemaciclib and aromatase inhibitor therapy after 18 months. She has no other comorbidities, and ctDNA analysis reveals an ESR1 mutation. Which of the following would be the ideal option at this time?
Powered by QuestionPro